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Endobariatric procedures for obesity:
clinical indications and available options
Hemant Goyal* , Jonathan Kopel*, Abhilash Perisetti*, Rupinder Mann, Aman Ali,
Benjamin Tharian, Shreyas Saligram and Sumant Inamdar

Abstract: Obesity remains a growing public health epidemic that has increased healthcare
costs and related comorbidities. Current treatment guidelines encourage a multidisciplinary
approach starting from patient selection, interventions, and long-term follow-up to maintain
weight loss. However, these conservative interventions are largely ineffective at reducing
body weight due to low adherence to the treatment regimen. Recently, endoscopic bariatric
therapies have become an attractive alternative to traditional invasive bariatric surgeries
due to their improved efficacy, safety, and cost-effectiveness. Endoscopic bariatric therapies
include intragastric balloon placement, endoscopic sleeve gastroplasty, gastric bypass
revision, and aspiration therapy. These procedures fall into two separate categories depending
on the primary mechanism involved: restrictive or malabsorptive. Restrictive methods, such
as the Orbera® and ReShape™ intragastric balloons, increase satiation and delay gastric
emptying while decreasing the amount of food that can be ingested. In contrast, malabsorptive
devices, such as the EndoBarrier®, interfere with the small intestine’s ability to absorb food
while restoring normal gastrointestinal hormone levels regulating satiation. Together, these
techniques provide useful alternatives for patients in whom pharmacological or lifestyle
modifications have proven ineffective. Despite these advantages, the long-term effects of
these procedures on metabolic changes remain to be studied. Furthermore, the management
of complications from these procedures continues to evolve. In this review, we aim to
elaborate on the clinical indications and efficacy of the endobariatric procedures, together
with various types of available endoscopic bariatric therapy procedures.
Keywords: bariatric surgeries, endoscopic bariatric therapy, obesity, Roux-en-Y gastric
bypass, weight loss
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Introduction
Obesity is a significant public health epidemic with
an increasing number of related complications with
rising healthcare costs.1–3 The prevalence of obesity
has doubled since the 1980s, with the World Health
Organization (WHO) 2014 estimates of 600 million
obese adults.1 Studies have shown that bariatric surgery improves obesity-related complications along
with the improved quality of life.4–6 Previous methods for controlling obesity and insulin resistance
used a combination of pharmacological and lifestyle
changes7,8; however, a meta-analysis of these interventions showed limited efficacy in reducing body
weight and adherence to the treatment regimen.7–10
Although the precise mechanisms of the effects of

Review

conservative approaches for weight loss remain
unclear, it could be due to the compensatory
increase in ghrelin in response to dietary manipulation. Bariatric surgeries have shown a more robust
response in achieving a higher total body weight
(TBW) loss and addressing metabolic dysfunction.7–10 Recent developments using endoscopic
bariatric therapies (EBTs) have proven safer, costeffective, and reversible alternative to traditional
surgical bariatric procedural methods.1,11,12
Bariatric surgeries are of several types, such
as Roux-en-Y gastric bypass (RYGB), sleeve
gastrectomy, adjustable gastric band, vertical
banded gastroplasty (VBG), duodenal switch,
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Table 1. Restrictive and Malabsorptive EBT Procedures.
EBT procedure

Definition

Example

Restrictive

Space-occupying balloons achieve restriction of the size of
gastric lumen. A balloon is filled with a methylene bluesaline solution to fill the stomach to induce early satiety.

Intragastric balloon
(Orbera®, ReShape™,
Obalon®)12,16

Malabsorptive

A duodenal-jejunal bypass sleeve is opened at the
duodenal bulb and extends into the small bowel. It
creates a mechanical barrier that forces food to bypass
the duodenum and proximal jejunum without mixing with
pancreaticobiliary secretions altering gut hormones.

Endoluminal
malabsorptive device
(EndoBarrier®)12,16

EBT, endoscopic bariatric therapies.

and biliopancreatic diversion (BPD).1 First
developed in the 1980s, EBTs include both gastric and small bowel interventions.1 Gastric intervention stimulates mechanical receptors mostly
in the gastric fundus to delay gastric emptying
and modify orexigenic hormones, including ghrelin and neuropeptide-Y (NPY).13,14 In contrast,
small bowel interventions bypass the stomach to
influence satiety and gastrointestinal (GI) motility.13,14 Currently, EBTs include the following
endoluminal procedures: intragastric balloon
(IGB) placement, endoscopic sleeve gastroplasty
(ESG), gastric bypass revision, and aspiration
therapy, and so on.15 These procedures fall into
two separate categories depending on the primary mechanism of action involved: restrictive or
malabsorptive (Table 1). Both restrictive and
malabsorptive methods improve weight loss by
altering gastric function, GI hormones, and GI
motility.1,7 Restrictive methods, such as the
Orbera® and ReShape™ IGBs, increase satiety
and delay gastric emptying while decreasing the
amount of food that is ingested.15 In contrast,
malabsorptive devices, such as the EndoBarrier®,
interfere with the small intestine’s ability to
absorb food while restoring normal GI hormone
levels regulating satiety. Together, EBTs have
provided a useful alternative for patients in whom
pharmacological or lifestyle modifications have
proven ineffective.7
Furthermore, EBTs also improve obesity-related
comorbidities, including type 2 diabetes (DM-2),
dyslipidemia, and nonalcoholic fatty liver disease
(NAFLD).17 Due to these benefits, endoscopic
weight loss therapies are considered another alternative for weight loss because of their lower risk
profile, increasing availability, minimal anatomic
alteration, and potential of reversibility compared
with surgical bariatric procedures.7 In addition,
2

EBTs have also positively impacted the quality of
life and the patients’ psychological aspects.18
Although bariatric surgical techniques have
improved over time, strict preoperative surgical/
anesthesia criteria and postoperative complications limit the use of bariatric surgeries.1,19,20 A
longitudinal assessment of these procedures found
that patient characteristics and past medical history can significantly influence surgical outcomes
and complications.20 Despite all the advances,
bariatric surgeries’ adverse event rate remains
as high as 17%.21 Due to these factors, minimally
invasive surgical procedures are being actively
sought. We explored PubMed, Google Scholar,
Embase, Ovid MEDLINE, CINAHL (via
ESBSCOhost) databases for articles published in
English languages up to July 15, 2020. The following search formula was used with words:
‘Gastroplasty’ or ‘Overstitch’ or ‘Endosleeve’ or
‘Endoscopic sleeve gastroplasty’ or ‘Endoscopic
bariatric therapy’ or ‘Endoscopic suturing’ or
‘Bariatric endoscopy’ or ‘Endobariatrics’) AND
(‘Weight loss’ or ‘Obesity’ or ‘Bariatric’) AND
(‘Endoscopic’). In this article, we will review the
indications for different EBTs along with their
potential complications. In addition, we will also
examine the putative mechanisms of actions and
future directions for EBTs.
Molecular mechanisms of endobariatric
therapies
The exact mechanism of EBTs remains poorly
understood and a subject of controversy. However,
it is believed that alterations and reorganization of
the GI tract and microbiome may restore homeostatic mechanisms in weight loss, caloric intake, and
glycemic control.22 Similar to previous bariatric surgeries, EBTs increase TBW loss and improve metabolic profile (low-density lipoprotein cholesterol,
journals.sagepub.com/home/cmg
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blood glucose, triglyceride, and blood pressure) in
obese patients.14,16 Multiple changes including a
decrease in levels of ghrelin, increased insulin sensitivity, and delayed gastric emptying have also been
noted.14,23 Ghrelin is a hormone secreted by the
stomach, small intestine, pancreas, and brain. Its
primary function is to stimulate appetite, increase
food intake, and promote fat storage. Hence, reducing the levels of ghrelin might induce weight loss.7–10
In addition, an increase in small intestinal hormones, including glucagon-like peptide 1 (GLP-1),
peptide YY (PYY), and oxyntomodulin, was
noted.14 Many obese patients have dysbiosis with
significant alterations in the gut microbiota.14 This
dysbiosis negatively impacts the interaction of
microbiota, immune system, and host defenses
required for protecting and maintaining the normal
gut-liver homeostasis.14 Examination of gut microbiota in clinical and in vivo studies shows a decrease
in the ratio of Firmicutes/Bacteroidaceae bacteria after
EBTs. The increase in Bacteroides leads to accelerated enzymatic conversion of primary to secondary
bile acids, which increased the release of gastric
inhibitor peptide and GLP-1 1.14 Furthermore,
EBTs bypass the foregut and accelerate intestinal
transit time leading to an increase in secondary bile
acids in the distal gut.14 The increase in secondary
bile acids induces the secretion of incretins, which
increases insulin levels while reducing blood glucose
levels.14 Therefore, reducing obesity through the
above mechanisms and lifestyle modification would
reverse the dysbiosis to achieve homeostasis.14
Costamagna and colleagues conducted a study to
assess the role of jejunum in insulin resistance in
humans and animals. In humans, 24 subjects with
obesity and insulin resistance but normal glucose
tolerance undergoing BPD (n = 12) or RYGB
(n = 12) were included. In the animal study, four
pigs were included; their jejunum was excluded
from intestinal continuity and attached its proximal and distal ends to the skin, thus creating a
jejunal loop with intact vascular and nerve supply;
the remaining bowel was reconnected with an
end-to-end anastomosis. The patient underwent
an oral glucose tolerance test in the human study
before and 1 week after BPD or RYGB. In the
animal study, glucose stable isotope was either
given in the stomach or the jejunal loop. It showed
that whole-body insulin sensitivity (SI.104)
increased from 0.54 ± 0.12 to 0.82 ± 0.11 one
week after BPD, p = 0.024. Similarly, SI.104
improved from 0.41 ± 0.09 to 0.65 ± 0.09 one
week after RYGB, but it was statistically significant. In the animal model, insulin sensitivity was
journals.sagepub.com/home/cmg

significantly higher when glucose was injected into
the stomach than in the jejunal loop (3.25 ± 0.50
vs 1.10 ± 0.32/pM/min, p = 0.0062). It also
showed that stimulation of myoblast with plasma
from subjects undergoing BPD and pigs during
gastric load after jejunectomy increased Ser473Akt phosphorylation and GLUT 4 expression
compared with subjects undergoing RYGB and
pig’s jejunal loop. These results showed that jejunum plays a vital role in insulin sensitivity, and
BPD may be superior to RYGB regarding improving glycemic control.24
A summary of the molecular mechanisms is
shown in Figure 1.
Society guidelines
Although no formal guidelines exist for EBTs
in the United States, the American Society for
Gastrointestinal Endoscopy (ASGE) has published
preliminary recommendations for the use of EBTs in
patients with obesity (Table 2). EBTs have been
noted to be superior to lifestyle interventions and
pharmacotherapy alone, with reduced adverse events
in randomized controlled trials (RCTs).25 EBTs are
primarily recommended for patients who have failed
non-surgical weight loss or weight maintenance with
lifestyle intervention alone and have medical conditions requiring weight loss for additional benefits.
Accredited hands-on training programs possibly with
formal teaching should be developed in conjunction
with GI societies that are focused on the understanding of the management of patients with obesity,
establish procedural competency, formal credentialing, and device-specific knowledge.26–28
Routine laboratory testing of complete blood count,
fasting blood glucose, lipids, kidney function, liver
function tests, urinalysis, prothrombin time/international normalized ratio, and nutritional screening
(25-hydroxy vitamin D, iron levels, vitamin B12,
and folic acid) should be analyzed before consideration for endobariatric procedures. Patients should
be evaluated for medical history, physical examination, screening for obesity-related diseases, and lifestyle changes. Further assessment of a patient’s
nutrition status, eating patterns, and registration
with a dietician is recommended before surgery.
Calorie restriction and exercise are an essential step
in patients undergoing bariatric interventions. For
example, after RYGB, caloric intake should be
reduced to 500 to 970 kcal/day in the first 3 months,
with a gradual increase to 870 to 1420 kcal/day at 1
year.26–28 Patients are also encouraged to perform
3
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Figure 1. Mechanisms of Weight Loss After Endoscopic Bariatric Therapy (EBT).

Figure showing mechanisms of weight loss after EBT. Three major pathways exist after EBT. Change in gut peptide levels,
bile acid signaling pathways, and altered gut microbiota. The pathways can interact with each other, producing increased
insulin sensitivity, lipid metabolism, and energy expenditure, ultimately leading to weight loss. EBT, Endoscopic bariatric
therapy; GIP, gastric inhibitory peptide; GLP-1, glucagon like peptide 1; FXR, farnesoid X receptor; TGR5, Takeda G protein–
coupled receptor.

Table 2. ASGE Endoscopic Bariatric Surgery Guideline Summary.25
Category

Recommendation

Inclusion Criteria

Patients who have failed weight loss or weight maintenance with lifestyle
intervention alone

Accreditation

Gastroenterology fellowship or general surgery residency

Pre-operative
Screening

Assess a patient’s nutrition status, eating patterns, and registration with a dietician.
Routine laboratory testing for complete blood count, lipids, kidney function, liver
function tests, urinalysis, and nutritional screening

Post-operative
Maintenance

Reduce caloric intake and increase exercise; provide long-term follow-up care
maintain weight loss and documented long-term complications

150 min and 200–300 min per week of moderateintensity exercise to lose weight or maintain weight,
respectively. This exercise regime should be complemented with behavior modification, such as
slowing the rate of eating, social support, cognitive restructuring, and relapse prevention. Postoperatively, patients should be enrolled for longterm follow-up care to determine the extent and
maintenance of weight loss and document any longterm complications. Further research and long-term
studies in the United States and abroad are needed
to establish therapeutic guidelines.
Types of endobariatric procedures
EBTs are mainly categorized into two categories: restrictive or malabsorptive procedures for
4

patients with a body mass index (BMI), mainly
between 30 and 45 kg/m2.
Restrictive EBT procedures
In restrictive EBTs, a balloon filled with methylene
blue-saline solution or inert gas is placed to fill the
stomach to induce early satiety by reducing the
available gastric lumen size. One of the first restrictive EBTs was IGB placements. In 1989, the first
IGB EBT was developed in the United States,
known as the Garren Edwards Gastric Bubble
(GEGB). GEGB was initially Food and Drug
Administration (FDA) approved in 1985 but was
later pulled from the market in 1992 after 7 years
because of issues with spontaneous deflation of the
bubble needing surgical removal.1,29–31 Moreover,
journals.sagepub.com/home/cmg
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Table 3a. Types of Intragastric Balloons and Their Respective Individual Outcomes.
Balloon type

Weight loss (%)

Implantation

Placement
method

Composition

FDA approval

Orbera®

Pooled metaanalysis
TWL: 13.637

6 months

Endoscopic

Silicone Sphere
(saline)

Yes; BMI
30–40 kg/m2;
Age 22–60

ReShape™

EWL: 31.8 ± 21.338

6 months

Endoscopic

Silicone Sphere
(saline)

Yes; BMI
30–40 kg/m2;
Age 22+

Spatz®

EWL: 26.439

12 months

Endoscopic

Silicone Sphere

No

Heliosphere®
Bag

EWL: 33.240

6 months

Endoscopic

Polyurethane
and silicone (Air)

No

MedSil®

EWL: 19.3 ± 12.741

6 months

Endoscopic

Silicone (Saline)

No

LexBal

EWL: 26.8 ± 12.342

6 months

Endoscopic

Silicone (Saline)

No

End-Ball®

EWL: 31.143

6 months

Endoscopic

Polyurethane
(Air/Saline)

No

Silimed

EWL: 46.5 ± 36.744

6 months

Endoscopic

Silicone(Saline)

No

Medicone®

TWL: 18.4 ± 2.945

6 months

Endoscopic

Silicone (Saline)

No

Semisationary
and balloon

EWL: 8.35 ± 6.446

6 months

Endoscopic

Silicone (Saline)

No

BMI, body mass index; EWL, excess weight loss; TWL, total weight loss.
The data presented in this table are for representation purposes only. This table, in no manner, depicts the comparison
between these devices.

studies showed that GEGB did not have any added
benefit compared with sham insertion combined
with a standard weight loss program. Therefore, it
was taken off the market in 1988.29,31 Later, more
effective and safer IGBs, such as the Orbera,
ReShape, and Obalon®, were developed and
launched.1,29,32–34 Orbera is one of the most effective types of EBTs for TBW loss and associated
with fewer adverse events based on clinical studies.32,35,36 Table 3(a) shows different IGBs, and
Table 3(b) shows other restrictive EBT studies.
Orbera and ReShape. The Orbera IGB (Apollo
Endosurgery, Inc., Austin, TX, USA) is a silicone
balloon that is endoscopically placed in the gastric
fundus, approved by the FDA in 2015. Patients
who received Orbera showed a 47% delay in gastric emptying and a 32.1% decrease in excess body
weight 6 months after implantation.50 These balloons are temporary, placed for 6 months, and can
be replaced later. The attained weight loss was corresponding to the extent of gastroparesis achieved
that, in turn, varied with the volume of the
journals.sagepub.com/home/cmg

balloon.51 After 36 months with Orbera, patients
had a long-term weight loss of 6%.50,52 A subsequent study in the United States showed a similar
reduction in TBW (10.54%) than the control
group.53 The Orbera is relatively safe, with nausea
and vomiting as the most common adverse events.
Serious events such as bowel obstruction (0.8%)
and gastric perforation (0.1%) are rare.36
A subsequent modification to the Orbera, known
as the ReShape IGB (Apollo Endosurgery, Inc.),
used two silicone balloons connected with a flexible tube placed endoscopically into the stomach.
The initial studies on ReShape showed that
patients had a 31.8% increase in excess weight
loss (EWL) compared with patients on a behavioral modification program.53 A larger US study
examining 326 patients showed that ReShape had
a 25.1% increase in EWL than the control
group.38 FDA has advised for adequate training
and close monitoring after Orbera placement.54–56
ReShape balloon is currently not available after
its withdrawal from the market.
5
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Table 3b. Restrictive Endoscopic Bariatric Therapy (EBT) Studies.
Device

Weight loss (%)

FDA approval

Complications14,47,48,49

TransPyloric Shuttle®

TWL: N/A
EWL: 31.3–50%

Yes; BMI 30–40 kg/m2

Stomach pain, nausea,
vomiting, and dyspepsia

Incisionless Anastomosis
System

TWL: %
EWL: 49.4%

No

N/A

AspireAssist®

TWL: N/A
EWL: 49.0%

Yes; BMI 30–40 kg/m2

Indigestion, nausea, vomiting,
constipation, and diarrhea

Botulinum Toxin A

TWL: N/A
EWL: N/A

No

Nausea and vomiting

Endoscopic Sleeve
Gastroplasty (ESG)

TWL: 20.9 %
EWL: 60.4 %

No

Nausea, bleeding, abdominal
infection, and stomach leak

Longitudinal Compression
Sutures with ESG

TWL: N/A
EWL: N/A

No

N/A

BMI, body mass index; EWL, excess weight loss; TWL, total weight loss.
The data presented in this table are for representation purposes only. This table, in no manner, depicts the comparison
between these devices.

Spatz®. The Spatz® IGB (Spatz Medical, Great
Neck, NY, USA) uses a silicone balloon that is
endoscopically inserted and inflated using saline,
which can be adjusted to reduce adverse side
effects and increase weight loss.14 This device has
not received FDA approval yet. The adjustment
also allows the balloon to remain safely inserted
in the stomach for a year.14 Although not approved
in the United States, recent studies using the
newer version (Spatz3®) IGB showed 26.4% and
38.8% EWL 6 and 12 months after being inserted
into the stomach.39 However, 39% of patients
who had the Spatz® balloon removed early developed catheter shear, perforating gastric ulcer,
deflation, gastritis, and Mallory-Weiss tears.39
Another study from the United Kingdom showed
that the Spatz3® increased EWL to 45.7% compared with the control.57 However, nearly 30% of
the patients had the Spatz3® IGB inserted for less
than 12 months due to intolerance, adjustment
refusal, and premature satisfaction.57
Heliosphere® Bag. Heliosphere Bag is an airfilled double-bag polymer balloon covered with a
silicone envelope. It is lighter than a fluid-filled
balloon with a weight of approximately 30 g.58,59
In a prospective study of 17 patients with a mean
BMI of 46 ± 8 kg/m2 who had endoscopic
guided intragastric air-filled balloon placement,
patients had achieved a weight loss of 11 ± 9 kg
(p = 0.02) and 4 ± 3 kg/m2 (p < 0.01) decrease
in BMI from initial weight and BMI. Balloons
6

were removed after 6 months. Balloon removal
was more difficult but successful in 15 of 17
patients. One patient required surgery due to
balloon fragmentation, and others had distal
migration of the balloon.59 Another study of 82
patients with a mean BMI of 39.1 kg/m2 who
underwent placement of heliosphere bag for 6
months showed a mean weight loss of 14.5 kg
and a BMI decrease of 5.3 kg/m2. Two patients
had spontaneous deflation, with one needing
early surgical removal.40 This device is not FDA
approved yet.
End-Ball® (Endalis). End-Ball (Endalis) IGB is a
saline/air-filled spherical elastic balloon made of
polyurethane. It allows for various proportions of air
and saline. It is not FDA approved. However, it is
the most common IGB used in Korea.43,60 A retrospective study of 114 with BMI 33.5 kg/m2 who
underwent End-Ball IGB placement showed a 5.5–
6.4 reduction in BMI at the time of balloon removal
and 4.1 reductions at 1 year after balloon removal.
Out of 114, 12 patients had early balloon removal
due to intolerance, dissatisfaction, and esophagitis.
No serious adverse events were reported.61 Similarly, another study by Buzga and colleagues showed
a significant decrease in body weight (13.9 ± 5.1
kg), glycated hemoglobin (p < 0.001), and triglycerides (p < 0.001). Early abdominal pain, nausea,
and vomiting were reported after IGB insertion,
which resolved spontaneously in a few days. No
serious adverse events were reported.43
journals.sagepub.com/home/cmg
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Other IGBs such as MedSil®, LexBal, Medicone®,
Semistationary antral balloon, Silimed, and ATIIP
(EndogAst®) are also endoscopically implanted.
These are not FDA approved.60
TransPyloric Shuttle®. Previous IGB models had
balloons placed in the fundus of the stomach. A
recently developed device, which is known as the
TransPyloric Shuttle (TPS®) (BAROnova Inc.,
Goleta, CA, USA), used to have the balloon
placed at the transpyloric position between the
stomach and duodenum, which was approved by
the FDA in 2019.14,62 The TPS consists of a
spherical silicone attached to a smaller silicone
bulb.14 The device is inserted with a smaller and
larger bulb placed in the duodenum and stomach,
respectively, to work as a ‘ball-valve’.14 The pilot
study using the TPS in 20 patients showed an
increase in an EWL of 31.3% and 50.0% at 3 and
6 months, respectively.14 A clinical trial (ENDOBESITY II trial) is currently being conducted in
the United States to determine the efficacy and
safety of the TPS in a larger sample size (ClinicalTrials.gov Identifier: NCT02518685).
Incisionless anastomosis system. In recent years,
other types of EBTs have been developed, including the incisionless anastomosis system (IAM),
through which an endoscope is passed, and specialized instruments create full-thickness serosa
to serosa plications.14 However, the IAM is currently not approved by the FDA.63 The technique
is used to perform a procedure known as the Primary Obesity Surgery Endoluminal (POSE)
(USGI Medical, San Clemente, CA, USA) procedure. This procedure brings the gastric fundus
down to the gastroesophageal junction by placing
8–9 plications in the gastric fundus. Afterward,
3–4 plications are placed in the distal body.14 This
device tabularizes the stomach and hence accelerates gastric emptying. The first report of IAMPOSE in 45 patients showed an increased EWL
by 49.4% over 6 months.64 None of the patients
reported serious adverse events.64 A US clinical
trial (ESSENTIAL trial) found the EWL in IAMPOSE was higher (4.95%) than the sham treatment group (1.38%) over 12 months.47
AspireAssist®. A recent development in the EBTs
included introducing a percutaneous gastrostomy
tube pump known as the AspireAssist (Aspire
Bariatrics, King of Prussia, PA, USA). The device
removes part of an ingested meal through an
external skin port 20–30 min after consumption.
Initial studies found that the AspireAssist showed
journals.sagepub.com/home/cmg

a 49.0% increase in EWL compared with the controls.47 The FDA approved the AspireAssist in
2016 for a BMI of 45.63,65 A similar study in the
United States (Pathway trial) showed a comparable reduction in excess body weight reduction in
patients with the AspireAssist.66 It is a long-term
device and is kept for about 1 year unless desired
by the patient to maintain it for the long term.
The long-term complications of AspireAssist are
nausea or vomiting.
Botulinum toxin A. Recent reports have suggested
that Botulinum toxin A (BTX-A) can help lose
weight by delaying gastric emptying. BTX-A is a
selective acetylcholine inhibitor that blocks smooth
and striated muscles across the GI tract. It is
believed that BTX-A may improve weight loss by
delaying gastric emptying and inducing satiety
through inhibition of vagal-mediated intestinal
contractions.14 Despite some initial success, a
meta-analysis of eight studies using BTX-A for
weight loss was inconclusive on whether BTX-A
increased weight loss. Further research and investigation are needed to determine the efficacy and
safety of BTX-A compared with current restrictive
EBTs.
ESG. Similar to the first IGBs, the VBG had a
high failure rate with long-term complications.48
The VBG was subsequently replaced by the
EndoCinch endoluminal vertical gastroplasty
(EVG) (C.R. Bard Inc., Murray Hill, NJ, USA)
and the TransOral GAstroplasty (TOGA®) system (Satiety Inc., Palo Alto, CA, USA). The FDA
approved this device in 2015 for tissue opposition, but the ESG by this device is still not
approved by the FDA because of the lack of sufficient trials.63,67
In a multicenter prospective single-arm trial from
two tertiary-care medical centers, 67 patients
underwent TOGA procedure for morbid obesity
and then followed up for 12 months to assess the
safety and procedure efficacy. The percentage of
EWL was 29.3% ± 11.6, 36.8% ± 15.7, and
38.7% ± 17.1 at 3, 6, and 12 months, respectively.
At 12 months, excess BMI also was seen more in
patients with baseline BMI of <40 (52.2%) compared with patients with baseline BMI of ⩾40
(41.3%) with a p value of <0.05. Significant
improvement in the quality of life was seen at 6 and
12 months. This study showed that TOGA is a safe
and efficacious procedure, but further studies
needed to examine long-term safety as patients
were followed for 12 months, only.68
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Figure 2. The Apollo OverStitch™ Suturing System With a Double-Channeled Therapeutic Gastroscope.

Table 4. Various ESG Studies With Their Individual Outcomes.
Study

Endoscopic
suturing device

Number of
patients

Mean BMI

6 months
% TWL

BMI (kg/m2)
6 months

6 months
% EWL

Lopez-Nava and
colleagues69

Overstitch

154

38.3 ± 5.5

15.8 ± 7.1

32.0 ± 4.3

47.8 ± 29.4

Alqahtani and
colleagues70

Overstitch

1000

33.3 ± 4.5

13.7 ± 6.8

29.0 ± 5.3

64.3 ± 56.2

Fayad and
colleagues71

Overstitch

54

17.2

NA

NA

Sartoretto and
colleagues72

Overstitch

112

37.9 ± 6.7

14.9 ± 6.1

32.3 ± 3.2

50.3

Sharahia and
colleagues73

Overstitch

91

40.7 ± 7

14.4

NA

NA

Lopez-Nava and
colleagues74

Overstitch

248

37.8 ± 5.6

15.2

NA

NA

Abu Dayyeh and
colleagues23

Overstitch

25

35.5 ± 2.6

NA

NA

López-Nava and
colleagues75

Overstitch

55

37.7 ± 4.5

18.9 ± 9.5

31.1 ± 4.5

55.2 ± 23.8

Saumoy and
colleagues76

Overstitch

128

13.43

33.94

NA

Kumar and
colleagues77

Overstitch

77

36.1 ± 0.6

16.2 ± 0.7

NA

NA

Huberty and
colleagues78

Endomina

51

35.1

32.2

31

43.1

38.9

8

53 ± 17

BMI, body mass index; EWL, excess weight loss; TWL, total weight loss.
The data presented in this table are for representation purposes only. This table, in no manner, depicts the comparison
between these devices.

Currently, two systems are available for use for
ESG: the Apollo OverStitch™ (Figure 2) and
Endomina™ [Endomina, Endo Tools SA (STT),
Gosselies, Belgium]. Table 4 shows various ESG
studies with outcomes.
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Apollo OverStitch Suturing System creates a restrictive sleeve. It applies full-thickness sutures
alongside the stomach’s greater curvature through
a double-channel therapeutic gastroscope79,80
(Figure 3). It reduces the functional capacity of the
journals.sagepub.com/home/cmg
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Figure 3. AspireAssist® Weight Loss System.

stomach and increases satiety.23 In a large prospective observational study, 1000 consecutive patients
with BMI 33.3 ± 4.5 kg/m2 underwent ESG with
an overstitch system. The mean percentage of total
weight loss (TWL) was 8.9 ± 2.9%, 10.5 ± 4.5%,
13.7 ± 6.8%, 15.2 ± 8.3%, 15.0 ± 7.7%, and
14.8 ± 8.5% at 1, 3, 6, 9, 12, and 18 months,
respectively. Abdominal pain or nausea (92.4%)
was the most commonly reported complaint during the first 5 days after surgery. There was no
reported need for emergent intervention or mortality. Revision to sleeve gastrectomy or redo ESG
was done in 13 patients.70 A retrospective analysis
of a prospectively maintained database of 248
patients who underwent ESG with the OverStitch
system showed a percentage TBW loss of 15.2
[95% confidence interval (CI): 14.2–16.3] and
18.6 (95% CI: 15.7–21.5) at 6 and 24 months,
respectively. Five (2%) serious procedure-related
adverse events were noted.74 Another prospective
study of 91 patients who underwent ESG with an
overstitch system showed a mean percentage of
TBWL of 14.4%, 17.6%, and 20.9% at 6, 12, and
24 months, respectively. Mild symptoms like selflimiting nausea lasting < 48 h and mild to moderate abdominal pain lasting < 48 h were experienced
by 38% and 27.4% of patients, respectively. In
contrast, the serious adverse events occurred in
only one patient (1.1%), who had peri-gastric leak
management non-operatively.73 A study conducted in India on the outcomes of 55 patients
undergoing ESG showed improved weight loss,
TBW loss, and BMI a year after surgery.49 The
authors noted no serious adverse events.49
Endomina system is a single-use over-the-scope
suturing device assembled in the stomach with an
endoscope, and it enables physicians to do large
journals.sagepub.com/home/cmg

plications with transmural anterior-to-posterior
endoscopic sutures.58 In a multicenter prospective
trial, 51 patients with a mean BMI of 35.1 kg/m2
underwent ESG with an endoluminal suturing
device and then followed for 1 year. No serious
adverse events were reported. At 1-year follow-up,
overall EWL and TBWL were 29% and 7.4%,
respectively. During a follow-up gastroscopy performed in 30 patients, 88% of sutures were in
place.78 Similarly, two patients with a BMI of 40.5
and 37.7 kg/m2 underwent ESG with Endomina
suturing system. Within 3 months of the procedure, BMI was reported to down to 38 and 33.4
kg/m2 in these patients. Both patients reported
only mild upper abdomen ache but no major
adverse events.81 In a recent RCT, 71 patients with
a BMI of 30–40 kg/m2 were randomized to either
lifestyle modification plus ESG with Endomina
system (n = 45) or lifestyle modification alone
(n = 21). At 6 months, lifestyle modification plus
ESG with Endomina system group found to have
higher mean EWL (38.6% vs 13.4%, p < 0.001),
decrease in mean volume (41% vs 2.5%,
p < 0.001), and mean quality of life (52.8% vs
45.1%, p < 0.05) than in the lifestyle modification
alone group. Long-term follow-up for ESG with
Endomina system used along with lifestyle modification group showed % EWL of 51% and 41.3%
at 9 and 12 months, respectively. Although the
sample size is small in this study, it showed that
quality of life and weight loss improve dramatically
when ESG with Endomina system is used along
with lifestyle modifications.82
In June 2019, a consensus meeting of 47
endoscopists experienced in ESG with 1828 procedures was held in Brazil. The published results
of this study showed a TBWL of 18.2% in 1 year.
9
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Complications were reported in 0.82% of cases,
with hematemesis being most common. This
consensus group agreed on several consensus
statements such as indication, contraindication,
procedure techniques, and post-procedure follow-up.83 A meta-analysis examining 22 cohort
studies on ESG showed that the procedures were
effective at short-term weight loss with few
adverse risk events.84 However, a recent metaanalysis showed that ESG improved weight loss
compared with laparoscopic techniques with
fewer side effects.85 Furthermore, the weight loss
continued for up to a year.85
ESG is a restrictive endoscopic bariatric procedure
that is a potentially repeatable and reversible procedure.23 A retrospective analysis of 120 patients from
a prospective database who underwent ESG
resulted in mean percentage EWL, mean percentage TBWL, and mean Bariatric Analysis and
Reporting Outcome (BAROS) score at 12 months
as 44.4% (±19.5), 18.3% (±6.7), and 4.5 (±1.7),
respectively. Redo ESG procedure was performed
in four patients. New stitches were positioned to
avoid overlap with previous stitches, and old stitches
were removed during the second procedure. The
6-month follow-up was available for three patients
with mean % EWL, % TBWL, BAROS mean score
as 44.2% (range: 30.5–59.1%), 20.4% (range:
16.7–24.5%), and 6.3 (range: 6–7), respectively.
No peri-procedure complications were reported
after the redo procedure, and all four patients
reported excellent satiety after this redo procedure.86
Although this study had a small sample, it showed
promising results for a redo procedure.
Modifications to the procedures and devices used
in endoscopic sleeve surgery have significantly
improved previous EBT surgeries. The procedure
utilized a ‘longitudinal compression’ suture pattern, which distributes tension equally across
each stitch in the anterior-posterior and craniocaudal dimensions of the stomach.87 Patients who
underwent the longitudinal compression stitches
had a significant reduction in body weight, BMI,
and TBW loss compared with patients with the
traditional stitching method of endoscopic gastric
sleeve surgery.87 This procedure is not approved
by the FDA. A recent UK study demonstrated
that a modified endoscopic gastric sleeve surgery
resulted in superior weight loss compared with
previous EBTs and bariatric techniques.87
EndoZip™ (NitiNotes Surgical, Caesarea, Israel)
is a new fully automated, operator-independent,
10

endoluminal-sutured gastroplasty system. By approximating opposing walls of the stomach using
the endoscopic technique, it creates multiple
internal gastric segmentation. A single-center,
first-in-human study involving 11 patients with a
BMI of 30–40 kg/m2 was conducted to assess the
technical feasibility of EndoZip™ for the treatment of obesity. A median of three sutures were
placed, and the technical success of the procedure
was 100%. No intraprocedural complications
were reported, and only one patient respiratory
infection, which was attributed to general
anesthesia/and or procedure. The mean ± SD %
EWL and TBWL was 46.5 ± 28.6% and
13.5 ± 4.7% at 3 months and 54.3 ± 28.4% and
16.2 ± 6.0 (p < 0.001) at 6 months, respectively. Although this study showed promising
results, the sample size was small, so further large
studies are needed to study the efficacy and safety
of this procedure.88
Malabsorptive endobariatric procedures
The small intestine is the primary site for nutrient
absorption and regulator of glucose homeostasis.
The glucose homeostasis is maintained through
small peptides released by enteroendocrine cells
that modulate satiety and insulin secretion. Given
this process, malabsorptive EBTs improve weight
loss and insulin secretion by impeding nutrient
absorption and improving peptide secretion from
enteroendocrine cells.15 The food bypasses small
intestines with these methods improving weight
loss and glucose homeostasis. The primary mechanism for a precursor for malabsorptive EBTs is
based upon the surgical principles of the RYGB.15
The RYGB is a malabsorptive EBT procedure
that divides that stomach into a small pouch and
a large remnant. The smaller pouch is then connected to the jejunal Roux limb, which bypasses
the stomach, duodenum, and proximal jejunum.
Patients with RYGB showed a 27% increased
reduction in TWL and decreased long-term allcause mortality rate compared with the control
group.89 Further studies showed that RYGB
patients had resolved diabetes and restored ghrelin, GLP-1, PYY, and cholecystokinin (CCK)
within normal limits.90–92 Many advances have
occurred with the use of RYGB. Given its success,
three endoscopic devices/procedures, Endoluminal
Bypass, EndoBarrier, and Duodenal Mucosal
Resurfacing, were developed to mimic the efficacy
of the RYGB.14 Table 5 shows malabsorptive
endobariatric procedures.
journals.sagepub.com/home/cmg
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Table 5. Malabsorptive Endoscopic Bariatric Therapy (EBT) Studies.
Device

Weight loss (%)

FDA approval

Complications

EndoBarrier

TWL: N/A
EWL: 12.6%

Yes; BMI 30-40
kg/m2

Bleeding, device migration,
cholestasis, and pancreatitis

Endoluminal Bypass

TWL: N/A
EWL: 54%

No

Bleeding, stomal and marginal
ulcers, stomal stenosis, leaks, and
fistulas or pancreatobiliary disorder

Duodenal Mucosal
Resurfacing

TWL: N/A
EWL: N/A

No

Abdominal pain

BMI, body mass index; EWL, excess weight loss; TWL, total weight loss.
The data presented in this table are for representation purposes only. This table, in no manner, depicts the comparison
between these devices.

EndoBarrier. A common malabsorptive EBT procedure that mimics the RYBG is the EndoBarrier
(GI Dynamics, Inc., Watertown, MA, USA) or
duodenal-jejunal bypass sleeve (DJBS), now
renamed as duodenal-jejunal bypass linear
(DJBL). The device uses a 2-ft-long fluoropolymer sleeve, which extends from the duodenal
bulb to the proximal jejunum, thereby bypassing
nutrients from being absorbed by the duodenum.
Furthermore, pancreatic enzymes and bile acids
are prevented from mixing with the nutrients
until further down the jejunum. The reduced
nutrient absorption allows for weight loss in obese
patients. A meta-analysis showed that the EndoBarrier increased EWL by 12.6% compared with
current interventions.93 Furthermore, the EndoBarrier also improved fasting plasma glucose
(FPG), which allowed patients to reduce or discontinue the dose of their antidiabetic medications.93 A US clinical trial found that over 60% of
patients had greater than 5% TWL; a third of
patients also achieved a hemoglobin A1c level of
less than 7%.94 On average, it brought down the
HBA1c by around 1.5%.
However, there have been concerns about
sleeve migration/occlusion, pancreatitis, and liver
abscesses due to potential biliary occlusion. A
systematic review and meta-analysis of 38 studies
conducted on adverse events associated with
DJBL showed a total of 891 adverse events in
1056 patients. According to ASGE guidelines,
75.8%, 20.5%, and 3.7% of adverse events were
classified as mild, moderate, and severe events,
respectively. The anchor of DJBL led to 85% of
severe adverse events, and it included esophageal
and duodenal bulb perforation, DJBL anchor tissue overgrowth, and GI hemorrhage.95 Betzel and
journals.sagepub.com/home/cmg

colleagues conducted a study to determine the
efficacy and safety of DJBL with 24 months of
implantation time. The largest decrease in body
weight loss and glycemic control was achieved
during the first 9–12 months after implantation of
DJBL. Adverse events were observed in 68% of
patients. It was found to be better tolerated during the first 12 months as more patients were
required early removed during the 12–24 months
period due to increased adverse events during this
extended period. Given that maximal beneficial
effects and fewer adverse events are seen in the
first 12 months, this study recommended not to
extend implantation time beyond 12 months.96
Due to safety concerns, the FDA has not approved
this device yet, although the CE mark was initially
issued but was withdrawn.97
Endoluminal bypass sleeve. An additional modification to the EndoBarrier was developed with the
Endoluminal Bypass device (ValenTx, Inc. Carpinteria, CA, USA).98 The Endoluminal Bypass
consists of a sleeve attached to the gastroesophageal junction to create an endoluminal gastroduodenojejunal bypass like the RYGB. This
device is not yet approved by the FDA.63 A study
of 12 patients with the endoluminal bypass
showed a 54% increase in EWL over a year.98
However, 2 patients could not tolerate the device
due to nausea and vomiting, with only 6 of the 10
patients had the Endoluminal Bypass a year later.
Despite the intolerance to device, hypertension,
diabetes, and hyperlipidemia improved in all the
patients.98
Duodenal mucosal resurfacing. A more invasive
approach to the malabsorptive EBTs is the
duodenal mucosal resurfacing (DMR) (Fractyl
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Laboratories, Cambridge, MA, USA) or the
Revita™ (Fractyl Laboratories, Cambridge, MA,
USA) procedure.14 This procedure is not FDA
approved yet.64 DMR is a minimally invasive catheter-based upper endoscopic procedure. It involves
circumferential hydrothermal ablation of duodenal
mucosa via a wire-guided balloon catheter system
filled with heated water.99 It is believed to help the
mucosal remodeling and inactivate dysfunctional
enteroendocrine cells.14 The first-in-human study
using the DMR in patients with diabetes mellitus
type 2 showed a reduction in their hemoglobin A1c
levels by 1.2% at 6 months. However, a few patients
developed duodenal stenosis requiring endoscopic
dilatation.100 A recent multicenter prospective study
of 46 patients with BMI between 24 and 40 kg/m2
and diabetes mellitus type 2 was conducted to evaluate the safety and efficacy of DMR. At 24 weeks
after the procedure, glycated hemoglobin, FPG, and
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) were reduced by 10 ± 2 mmol/
mol, 1.7 ± 0.5 mmol/L, and 2.9 ± 1.1, respectively, compared with baseline with a p value of
<0.001. During the first-year follow-up, 52% of
patients reported adverse events, but most of these
adverse events were mild.101 In a review of four clinical studies, 79 DMR patients were reported to have
significant short-term metabolic effects with statistically significant (p < 0.001) reduction of mean
HbA1c, FPG, and HOMA-IR of 0.9 ± 0.2%,
1.7 ± 0.5 mmol/L, and 2.9 ± 1.1 mul/L, respectively. Mild postoperative adverse events were
reported in 64% of cases and severe adverse events
in 3.7% of cases.102
Future directions
EBTs are used regularly to treat bariatric surgery
complications and for revision of the former when
there is weight regain. This combination of weight
loss pharmacotherapy (e.g. Liraglutide) and various
EBTs has recently gained more traction.103 The
treatment has to be personalized to match the intervention/device to the physiological phenotype of the
individual to optimize outcomes. The phenotype
may be decided based on gastric emptying, especially when deciding between various restrictive
modalities.17 Likewise, pouch size and outlet size
might be utilized to decide between plication and
suturing.104 The newer devices on the horizon
include Endosleeve™ by Metamodix to treat metabolic syndrome; the endoluminal magnets would
create a side-to-side entero-enteric anastomosis.
Beyond treating obesity, EBTs have applications in
other medical therapies, including bridging therapy,
12

cosmetic therapy, and bariatric surgery revision.14
Despite its broad applications, further studies are
needed to understand the mechanisms of actions of
each EBT and their surgical outcomes for longterm weight loss maintenance and personalized
therapy.103 EBT procedures may provide alternatives for screening obese patients for long-term
complications, using minimally invasive endoscopic
procedures. For example, transnasal endoscopy
(TNE) is competent at evaluating obese patients
before bariatric surgery without the need for sedation.105 EBTs are becoming an essential tool for
improving sustained weight loss in obese patients
without long-term adverse effects.7,14 Similar to traditional bariatric surgery, EBTs are effective at controlling metabolic comorbidities, lowering adverse
risk events, and improving overall weight loss among
obese patients.7,14
Several new EBTs are being investigated currently,
including Endoscopic Gastric Mucosal Devitalization (ClinicalTrials.gov identifier: NCT03526263,
NCT03638843, and NCT03288259). Similarly,
clinical trials are examining new suture devices
and techniques, such as the Endoluminal-suturing
Device, which will improve EBT outcomes and
reduce short- and long-term surgical outcomes
(ClinicalTrials.gov identifier: NCT03900481 and
NCT01067625). Studies in the future should
evaluate the mechanism and long-term treatment outcomes for EBTs compared with traditional bariatric surgeries (ClinicalTrials.gov
identifier: NCT04006002, NCT01871896, and
NCT03705416). Together, all these will advance
the efficacy of EBTs and establish accepted
guidelines for its more extensive use among obese
patients and a global acceptance by the medical
community.
Conclusion
EBTs remain an evolving, minimally invasive surgical technique that improves surgical outcomes,
prognosis, and surgical complications. It has been
shown that the single most important independent
predictor of success regardless of the type of endobariatric treatment received was the adherence to
outpatient follow-up. Further studies are needed to
establish guidelines for EBT devices, surgical techniques, long-term outcomes, and complications.
EBTs and surgical protocols may be combined
with traditional bariatric surgery techniques to
improve surgical outcomes, reduce adverse surgical
events, and reduce obesity-related comorbidities.
Furthermore, endoscopic procedures can also help
journals.sagepub.com/home/cmg
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screen the anatomy, function, and pathological
findings of an obese patient’s foregut for any risk
factors influencing the long-term outcome of bariatric surgeries or EBTs. High-quality RCTs are
required to examine whether combined EBTs with
bariatric surgery or interventions can improve therapeutic outcomes and help establish guidelines for
the safe application and success of EBTs in the
future.
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